Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237357 | 1.00 | ALDH1A1 (0.65) | ALDH1A1NPC1MTORHPGDLMNA | |
| SCHEMBL25282379 | 0.85 | NPC1 (0.67) | NPC1MTOR | |
| SCHEMBL29411871 | 0.85 | NPC1 (0.67) | NPC1MTOR | |
| SCHEMBL8980379 | 0.85 | NPC1 (0.57) | NPC1MTOR | |
| SCHEMBL22476146 | 0.85 | ALDH1A1 (0.48) | ALDH1A1NPC1MTORHPGDLMNA | |
| SCHEMBL8980373 | 0.85 | — | — | |
| SCHEMBL18294606 | 0.85 | — | — | |
| SCHEMBL8980231 | 0.85 | NPC1 (0.57) | NPC1MTOR | |
| SCHEMBL8980461 | 0.85 | NPC1 (0.57) | NPC1MTOR | |
| SCHEMBL8980306 | 0.84 | NPC1 (0.57) | NPC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302488-B1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC (TW) | 2020-09-30 | — | — | EP | disclosed |
| US-9717721-B2 | Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | TAIRX, INC. (TW) | 2017-08-01 | — | — | US | disclosed |
| US-9717721-B2 | Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | TAIRX, INC. (TW) | 2017-08-01 | — | — | US | disclosed |
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC. (TW) | 2016-12-08 | — | — | US | disclosed |
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC. (TW) | 2016-12-08 | — | — | US | disclosed |
| US-9029394-B2 | 2-phenyl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-12 | — | — | US | disclosed |
| US-9029394-B2 | 2-phenyl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-12 | — | — | US | disclosed |
| US-9023867-B2 | Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-9023867-B2 | Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-9023866-B2 | 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-19 | — | — | US | disclosed |
| US-8440692-B2 | Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-05-14 | — | — | US | disclosed |
| US-8440692-B2 | Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-05-14 | — | — | US | disclosed |
| EP-2468747-A1 | 2-Selenophene-4-quinolones as anticancer agents | China Medical University (TW) | 2012-06-27 | — | — | EP | disclosed |
| EP-2455369-A1 | Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents | China Medical University (TW) | 2012-05-23 | — | — | EP | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| WO-2008070176-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2008-06-12 | — | — | WO | disclosed |
| US-5571822-A | AMINO-2-PHENYL-4-QUINOLONE DERIVATIVES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996010563-A1 | 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, SLC20A1 | ALDH1A1 3332/4885NPC1 3939/4885MTOR 1486/4885 |
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TEK, FLT1, VHL | ALDH1A1 1091/4885NPC1 4748/4885MTOR 2397/4885 |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | ALDH1A1 3130/4885NPC1 4192/4885MTOR 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.